Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indian market for transplant products is pegged at $36 million and is expected to grow in double digits.
You may also be interested in...
Astellas Takes First Steps In India With Prograf
TOKYO - Astellas Pharma said April 12 that its Indian subsidiary has commenced marketing immunosuppressant Prograf (tacrolimus), its flagship product, in India, in the company's first stab at the world's second most populous country
Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders
To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.